Champions Oncology Inc 的盈利质量评分为 B+/48.27046。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Champions Oncology Inc 何时发布财报?
Champions Oncology Inc 的下一份财报预计在 2026-06-10 发布
Champions Oncology Inc 的预期收益是多少?
根据华尔街分析师的预测,Champions Oncology Inc 的预期收益为 $16.94M
Champions Oncology Inc 是否超出收益预期?
Champions Oncology Inc 最近的收益为 $16.55M,未达预期 预期。
关键数据
前收盘价
$5.8
开盘价
$5.8
当日区间
$5.8 - $5.89
52周范围
$5.5 - $9.97
交易量
7.2K
平均成交量
7.0K
股息收益率
--
每股收益(TTM)
0.17
市值
$81.1M
什么是 CSBR?
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.